Implantable device curbs seizures and improves cognition in epileptic rats
A protein-secreting device implanted into the hippocampus of epileptic rats reduces seizures by 93 percent in three months, finds preclinical research published in JNeurosci. These results support ongoing development of this technology and its potential translation into a new treatment for epilepsy.
Motivated by an unmet need for effective and well-tolerated epilepsy therapies, Giovanna Paolone and colleagues of the University of Ferrara, Italy and of Gloriana Therapeutics, Inc. (Providence, RI) investigated the effects of the Gloriana targeted cellular delivery system for glial cell line-derived neurotrophic factor (GDNF) — a protein recent research suggests may help suppress epileptic activity.
In addition to quickly and progressively reducing seizures in male rats — by 75 percent within two weeks — the researchers found their device improved rats’ anxiety-like symptoms and their performance on an object recognition task, indicating improvement in cognition.
The treatment also corrected abnormalities in brain anatomy associated with epilepsy. These effects persisted even after the device was removed, indicating this approach may modify the disease progression.
The Latest on: Epilepsy treatment
via Google News
The Latest on: Epilepsy treatment
- Neurocrine Biosciences and Idorsia Amend Option Agreement to License Novel Treatment for Rare Pediatric Epilepsyon January 10, 2020 at 6:31 am
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and Idorsia Ltd. (SIX: IDIA) announced an amendment to the agreement that was originally signed in 2019 granting Neurocrine Biosciences an option to license ...
- BRIEF-Idorsia And Neurocrine Biosciences Amend Option Agreement On Treatment For Pediatric Epilepsyon January 9, 2020 at 10:43 pm
Our Standards:The Thomson Reuters Trust Principles.
- BRIEF-Neurocrine Biosciences And Idorsia Amend Option Agreement To License Novel Treatment For Rare Pediatric Epilepsyon January 9, 2020 at 10:31 pm
NEUROCRINE- IDORSIA TO RECEIVE $45 MILLION UPFRONT UPON EXERCISE OF OPTION, UP TO $365 MILLION IN POTENTIAL DEVELOPMENT, REGULATORY MILESTONE PAYMENTS * NEUROCRINE BIOSCIENCES-OWNS OPTION TO ...
- Idorsia Pharmaceuticals Ltd: Neurocrine Biosciences and Idorsia amend option agreement to license novel treatment for rare pediatric epilepsyon January 9, 2020 at 9:05 pm
Neurocrine Biosciences owns option to exclusively license ACT-709478, a clinical stage selective T-type calcium channel blocker for the treatment of epilepsy Idorsia to receive $45 million upfront ...
- Long-term epilepsy-associated tumors: transcriptional signatures reflect clinical courseon January 9, 2020 at 3:17 am
Consequently, the oncological aspect should be also considered during the treatment decision-making process 21. Here, we present a comprehensive clinical, pathological and molecular analysis aiming at ...
- Odgers Berndtson awarded Epilepsy Foundation CEO Searchon January 7, 2020 at 4:42 pm
Odgers Berndtson, a top-six global executive search firm, is pleased to announce that they have been awarded the national search for the President and CEO for the Epilepsy Foundation. The search will ...
- Advances in Health: Next-Gen Treatment for Epilepsyon January 7, 2020 at 5:00 am
More than 2 million Americans will have a seizure at some point, but only one or two out of 100 actually have epilepsy. To get the most effective treatment, you must be diagnosed correctly. The ...
- Eisai's Fycompa for Adjunctive Treatment of Partial Onset Seizures Launched in Chinaon January 6, 2020 at 4:20 pm
TOKYO, Jan 6, 2020 - (JCN Newswire) - Eisai Co., Ltd. has launched the in-house discovered and developed antiepileptic drug (AED) Fycompa, (generic name perampanel) for use in the adjunctive treatment ...
- Epilepsy study shows link between brain activity and memoryon January 6, 2020 at 7:36 am
Using electrodes implanted in the brains of 11 adult epilepsy patients as part of their treatment, the team recorded activity of individual cells in the hippocampus during a recognition memory task.
- Extra benefit from epilepsy neurostimulators -- reducing comorbid neuropsychiatric symptomson January 2, 2020 at 11:56 am
All saw improvements from changes in drug treatment, cognitive behavioral therapy or counseling to reduce symptoms such as panic-like attacks, psychosis and psychogenic nonepileptic seizures. "The ...
via Bing News